- Home
- NFJ vs PCRX Comparison
NFJ vs PCRX Comparison
Compare NFJ & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFJ
- PCRX
- Stock Information
- Founded
- NFJ 2005
- PCRX 2006
- Country
- NFJ United States
- PCRX United States
- Employees
- NFJ N/A
- PCRX N/A
- Industry
- NFJ Finance: Consumer Services
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- NFJ Finance
- PCRX Health Care
- Exchange
- NFJ Nasdaq
- PCRX Nasdaq
- Market Cap
- NFJ 1.2B
- PCRX 1.2B
- IPO Year
- NFJ N/A
- PCRX 2011
- Fundamental
- Price
- NFJ $13.15
- PCRX $23.40
- Analyst Decision
- NFJ
- PCRX Buy
- Analyst Count
- NFJ 0
- PCRX 5
- Target Price
- NFJ N/A
- PCRX $32.40
- AVG Volume (30 Days)
- NFJ 223.5K
- PCRX 543.2K
- Earning Date
- NFJ 01-01-0001
- PCRX 11-05-2025
- Dividend Yield
- NFJ 9.01%
- PCRX N/A
- EPS Growth
- NFJ N/A
- PCRX N/A
- EPS
- NFJ N/A
- PCRX N/A
- Revenue
- NFJ N/A
- PCRX $705,848,000.00
- Revenue This Year
- NFJ N/A
- PCRX $7.36
- Revenue Next Year
- NFJ N/A
- PCRX $10.07
- P/E Ratio
- NFJ N/A
- PCRX N/A
- Revenue Growth
- NFJ N/A
- PCRX 2.25
- 52 Week Low
- NFJ $10.45
- PCRX $15.16
- 52 Week High
- NFJ $12.86
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- NFJ 62.28
- PCRX 30.26
- Support Level
- NFJ $12.99
- PCRX $23.09
- Resistance Level
- NFJ $13.23
- PCRX $26.05
- Average True Range (ATR)
- NFJ 0.12
- PCRX 0.69
- MACD
- NFJ 0.01
- PCRX -0.34
- Stochastic Oscillator
- NFJ 83.67
- PCRX 6.14
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.